



*ASX Limited  
Market Announcements Office*

## **Phosphagenics Signs Development Agreement with tesa Labtec GmbH for its TPM<sup>®</sup>/Oxymorphone Patch**

22 October 2015, Melbourne: Australian drug delivery company, Phosphagenics Limited (ASX: POH; OTCQX: PPGNY), has entered into a development agreement with tesa Labtec GmbH, the German transdermal formulation specialists, to undertake the continued development of its transdermal TPM<sup>®</sup>/Oxymorphone patch.

The objective is to build on the work done to date and create a transdermal patch product with suitable characteristics for development through to commercialisation. Once formulated, the patch will then be progressed towards an Investigational New Drug (IND) application with the US Food & Drug Administration.

Phosphagenics previously worked with tesa to develop the TPM<sup>®</sup>/Oxycodone patch, which is presently being investigated in a Phase 2 proof-of-concept study for Postherpetic Neuralgia (PHN).

Dr Ross Murdoch, CEO, said, "We assessed proposals from several potential partners before selecting tesa. We have confidence in their specialist skills and in their ability to complete the reformulation to a standard that will enable us, or a partner, to advance the program to commercialisation. Our previous work with TPM<sup>®</sup> and Oxymorphone has already demonstrated that it is possible to achieve impressive transdermal delivery and plasma levels within the recognised therapeutic range. This collaboration is designed to take that accumulated know-how and build it into a patch with all the desirable characteristics necessary for successful commercialisation by ourselves or potential partners."

**ENDS**

### **Enquiries**

Dr Ross Murdoch  
CEO  
Phosphagenics Limited  
+61 3 9565 1119

Rudi Michelson  
Monsoon Communications  
+61 3 9620 3333

## **About Phosphagenics**

Phosphagenics Limited is a drug delivery company that is commercialising various products within the pharmaceutical, cosmetics and animal health sectors, using its proprietary drug delivery system called TPM<sup>®</sup> (Targeted Penetration Matrix). TPM<sup>®</sup> is a patient friendly and cost effective system, based on Vitamin E, that enhances the topical or transdermal delivery of active molecules. The lead products advancing through clinical trials are oxymorphone and oxycodone patches for the relief of chronic pain.

Phosphagenics' shares are listed on the Australian Securities Exchange (POH) and its ADR – Level 1 program in the US is with The Bank of New York Mellon (PPGNY).

## **Inherent Risks of Investment in Biotechnology Companies**

There are a number of inherent risks associated with the development of pharmaceutical products to a marketable stage. The lengthy clinical trial process is designed to assess the safety and efficacy of a drug prior to commercialisation and a significant proportion of drugs fail one or both of these criteria. Other risks include uncertainty of patent protection and proprietary rights, whether patent applications and issued patents will offer adequate protection to enable product development, the obtaining of necessary drug regulatory authority approvals and difficulties caused by the rapid advancements in technology.

## **Forward-looking Statements**

Certain statements in this announcement may contain forward-looking statements regarding Company business and the therapeutic and commercial potential of its technologies and products in development. Any statement describing Company goals, expectations, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the process of discovering, developing and commercialising drugs that can be proven to be safe and effective for use as human therapeutics, and in the endeavour of building a business around such products and services.

[www.phosphagenics.com](http://www.phosphagenics.com)